Headlines about Boston Scientific (NYSE:BSX) have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Boston Scientific earned a news impact score of 0.19 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 45.6993590082739 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Accern’s scoring:
- Boston Scientific (BSX) Rating Reiterated by Cowen (americanbankingnews.com)
- Boston Scientific (BSX) Upgraded by Zacks Investment Research to “Hold” (americanbankingnews.com)
- Boston Scientific (BSX) Cut to “Sell” at BidaskClub (americanbankingnews.com)
- WATCHMAN to Aid Boston Scientific (BSX) Q1 Earnings Amid Woes (finance.yahoo.com)
- MitraClip Drives Growth, Gets Reimbursement Approval in Japan (finance.yahoo.com)
BSX stock traded up $0.08 during trading on Friday, hitting $28.31. 7,787,840 shares of the company’s stock traded hands, compared to its average volume of 6,596,739. The firm has a market cap of $38,813.74, a price-to-earnings ratio of 22.47, a PEG ratio of 2.04 and a beta of 0.81. The company has a quick ratio of 0.49, a current ratio of 0.68 and a debt-to-equity ratio of 0.54. Boston Scientific has a 1 year low of $24.31 and a 1 year high of $29.93.
BSX has been the topic of a number of research reports. Royal Bank of Canada reaffirmed a “top pick” rating and set a $32.00 target price on shares of Boston Scientific in a research report on Monday, March 5th. TheStreet raised shares of Boston Scientific from a “c+” rating to a “b” rating in a research report on Thursday, January 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $35.00 target price on shares of Boston Scientific in a research report on Tuesday, March 27th. Zacks Investment Research lowered shares of Boston Scientific from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, ValuEngine lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $31.45.
In other Boston Scientific news, CFO Daniel J. Brennan sold 60,209 shares of the firm’s stock in a transaction that occurred on Monday, March 19th. The shares were sold at an average price of $27.87, for a total value of $1,678,024.83. Following the completion of the sale, the chief financial officer now directly owns 299,644 shares in the company, valued at $8,351,078.28. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP David A. Pierce sold 5,152 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $27.43, for a total transaction of $141,319.36. Following the completion of the sale, the senior vice president now owns 29,353 shares of the company’s stock, valued at $805,152.79. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 238,903 shares of company stock valued at $6,497,699. 0.73% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This article was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://weekherald.com/2018/04/15/boston-scientific-bsx-given-daily-news-impact-score-of-0-19.html.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.